Drug company is reprimanded by UK regulatorBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7496.865-b (Published 14 April 2005) Cite this as: BMJ 2005;330:865
- Lynn Eaton
A drug company has been publicly reprimanded for trying to subvert a safety message issued by UK regulators for a drug used to treat depression and anxiety.
The Medicines and Healthcare Products Regulatory Agency, which monitors the safety of drugs, censured Wyeth last week after a health professional complained about the way that company representatives had openly questioned a safety warning on the drug venlafaxine (sold as Efexor and Efexor XL), a serotonin and noradrenaline reuptake inhibitor.
In December the Committee on Safety of Medicines warned of potential cardiac problems with the drug. Subsequent guidance from the National Institute for Clinical Excellence (NICE) on the treatment of depression states that mental health specialists using …